JPWO2020242896A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020242896A5 JPWO2020242896A5 JP2021569951A JP2021569951A JPWO2020242896A5 JP WO2020242896 A5 JPWO2020242896 A5 JP WO2020242896A5 JP 2021569951 A JP2021569951 A JP 2021569951A JP 2021569951 A JP2021569951 A JP 2021569951A JP WO2020242896 A5 JPWO2020242896 A5 JP WO2020242896A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleoside
- sequence
- composition
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076474A JP2025128091A (ja) | 2019-05-24 | 2025-05-01 | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852813P | 2019-05-24 | 2019-05-24 | |
| US62/852,813 | 2019-05-24 | ||
| US201962881906P | 2019-08-01 | 2019-08-01 | |
| US62/881,906 | 2019-08-01 | ||
| PCT/US2020/034063 WO2020242896A2 (en) | 2019-05-24 | 2020-05-21 | Treatment of angiopoietin like 7 (angptl7) related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076474A Division JP2025128091A (ja) | 2019-05-24 | 2025-05-01 | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535717A JP2022535717A (ja) | 2022-08-10 |
| JP2022535717A5 JP2022535717A5 (https=) | 2023-05-11 |
| JPWO2020242896A5 true JPWO2020242896A5 (https=) | 2023-05-11 |
Family
ID=73553086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569951A Pending JP2022535717A (ja) | 2019-05-24 | 2020-05-21 | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
| JP2025076474A Pending JP2025128091A (ja) | 2019-05-24 | 2025-05-01 | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076474A Pending JP2025128091A (ja) | 2019-05-24 | 2025-05-01 | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10941404B2 (https=) |
| EP (1) | EP3976059A4 (https=) |
| JP (2) | JP2022535717A (https=) |
| KR (1) | KR20220024153A (https=) |
| CN (2) | CN120022289A (https=) |
| AU (1) | AU2020285639A1 (https=) |
| CA (1) | CA3140917A1 (https=) |
| WO (1) | WO2020242896A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| JP2022523301A (ja) | 2019-01-23 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
| KR20220024153A (ko) | 2019-05-24 | 2022-03-03 | 엠피리코 인크. | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| WO2022182768A1 (en) * | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| EP4352231A4 (en) * | 2021-06-07 | 2026-02-11 | Empirico Inc | TREATMENT OF DISEASES ASSOCIATED WITH ANGPTL4 |
| US20240409943A1 (en) * | 2021-10-01 | 2024-12-12 | Alnylam Pharmaceuticals, Inc. | iRNA Compositions and Methods for Targeting ANGPTL7 |
| CN118632622A (zh) | 2021-12-08 | 2024-09-10 | 瑞泽恩制药公司 | 突变型肌纤蛋白疾病模型及其用途 |
| US20250197859A1 (en) * | 2022-03-28 | 2025-06-19 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| CN115624539A (zh) * | 2022-12-16 | 2023-01-20 | 首都医科大学附属北京朝阳医院 | 一种脂质纳米颗粒及其制备方法和应用 |
| WO2025042862A1 (en) * | 2023-08-18 | 2025-02-27 | The Johns Hopkins University | Modulation of nuclear envelope protein expression for alleviation of nuclear pore complex injury cascades and tdp- 43 dysfunction in neurodegeneration |
| CN118604350A (zh) * | 2024-05-17 | 2024-09-06 | 上海市第一人民医院 | 年龄相关性黄斑变性诊断的生物标志物、检测试剂盒及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US543227A (en) | 1895-07-23 | Core-drilling machinery | ||
| IE922292A1 (en) | 1991-07-15 | 1993-01-27 | Jolla Pharma | Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides |
| US20060148743A1 (en) * | 2001-05-18 | 2006-07-06 | Vasant Jadhav | RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) |
| US20090137507A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF ANGIOPOIETIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20040198640A1 (en) * | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| US7601501B2 (en) * | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
| JP2010505897A (ja) | 2006-10-11 | 2010-02-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | インフルエンザターゲット |
| US20110301228A1 (en) | 2009-02-11 | 2011-12-08 | The University Of North Carolina At Chapel Hill | Gene therapy vector for treatment of steroid glaucoma |
| EP3028707A1 (en) | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| EP2494351B1 (en) * | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Colon and rectal tumor markers and methods of use thereof |
| EP3260540A1 (en) * | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2780454A2 (en) | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| US9206423B2 (en) * | 2012-12-30 | 2015-12-08 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
| WO2014167529A1 (en) * | 2013-04-10 | 2014-10-16 | Institut De Cardiologie De Montreal | Methods and compositions for preventing and treating atherosclerosis |
| CN103509101B (zh) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | 一种扩增脐带血造血干细胞的细胞因子及其培养基 |
| WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
| JP6708630B2 (ja) * | 2015-04-17 | 2020-06-10 | 国立大学法人 東京大学 | 角膜障害の予防又は治療剤 |
| WO2016205488A1 (en) * | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| JP7420727B2 (ja) | 2018-02-17 | 2024-01-23 | アローヘッド ファーマシューティカルズ インコーポレイテッド | トリアルキン結合剤及び使用方法 |
| US11452738B2 (en) | 2019-01-04 | 2022-09-27 | Empirico Inc. | Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts |
| JP2022523301A (ja) | 2019-01-23 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
| US20220089664A1 (en) | 2019-01-23 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors |
| KR20220024153A (ko) | 2019-05-24 | 2022-03-03 | 엠피리코 인크. | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 |
| IL300283A (en) | 2020-08-04 | 2023-04-01 | Dicerna Pharmaceuticals Inc | Systemic administration of oligonucleotides |
| WO2022072356A1 (en) | 2020-09-29 | 2022-04-07 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| US20250197859A1 (en) | 2022-03-28 | 2025-06-19 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
-
2020
- 2020-05-21 KR KR1020217041991A patent/KR20220024153A/ko active Pending
- 2020-05-21 WO PCT/US2020/034063 patent/WO2020242896A2/en not_active Ceased
- 2020-05-21 JP JP2021569951A patent/JP2022535717A/ja active Pending
- 2020-05-21 AU AU2020285639A patent/AU2020285639A1/en active Pending
- 2020-05-21 CN CN202411735471.7A patent/CN120022289A/zh active Pending
- 2020-05-21 EP EP20813437.9A patent/EP3976059A4/en active Pending
- 2020-05-21 CA CA3140917A patent/CA3140917A1/en active Pending
- 2020-05-21 CN CN202080053392.1A patent/CN114375194B/zh active Active
- 2020-09-04 US US17/012,524 patent/US10941404B2/en active Active
-
2021
- 2021-01-22 US US17/156,421 patent/US12378556B2/en active Active
-
2025
- 2025-05-01 JP JP2025076474A patent/JP2025128091A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110846316B (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| JPWO2020242896A5 (https=) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP3926840B2 (ja) | 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用 | |
| ES2221955T3 (es) | Secuencias guia externas cortas. | |
| JP2020094063A5 (https=) | ||
| JP2020039354A (ja) | Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法 | |
| JP2018520685A5 (https=) | ||
| Stein et al. | Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV | |
| JP2018529732A5 (https=) | ||
| Leonetti et al. | Cell delivery and mechanisms of action of antisense oligonucleotides | |
| JP2003533986A (ja) | スプライス領域アンチセンス組成物および方法 | |
| JP2018528783A (ja) | コンジュゲートアンチセンス化合物及びその使用 | |
| JP2005500025A5 (https=) | ||
| RU2007132848A (ru) | Опосредуемое rnai ингибирование мишеней глаза | |
| JP2021505129A5 (https=) | ||
| JPWO2022032288A5 (https=) | ||
| WO2023034870A2 (en) | Compounds and methods for reducing dmpk expression | |
| EP4291651A1 (en) | Compounds and methods for reducing pln expression | |
| CN113795581A (zh) | 具有缩短的有义链的双链核酸抑制剂分子 | |
| JP2023530072A (ja) | Ｐｍｐ２２を調節するための化合物及び方法 | |
| JP2009512673A5 (https=) | ||
| JP7722666B2 (ja) | アンギオテンシン変換酵素２遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸 | |
| Li | Programmable DNA nanostructures for cell delivery | |
| KR20240110595A (ko) | 안정화된 rna 제제 |